Research Paper Volume 13, Issue 9 pp 13073—13086

MiR-205 suppressed the malignant behaviors of breast cancer cells by targeting CLDN11 via modulation of the epithelial-to-mesenchymal transition

miR-205 expression was downregulated in breast cancer. (A) Expression levels of miR-205 in breast cancer tissues and adjacent normal breast tissues as analyzed by the qRT-PCR assay. (B) The expression of miR-205 in breast cancer cell lines and normal cell MCF10A. (C) The expression of miR-205 in breast cancer patients with TNM stages was significantly reduced. (D) Both MCF7 and MDA-MB-231 cells were transfected with control miRNA or miR-205 mimics, and the expression of miR-205 was confirmed by qRT-PCR. (E) The association between expression of miR-205 and clinical characteristics of patients with breast cancer. LinkedOmics database with TCGA data was used for this analysis. All experiments were carried out in triplicate. Data were expressed as mean ± standard deviation (SD).

Figure 5. miR-205 expression was downregulated in breast cancer. (A) Expression levels of miR-205 in breast cancer tissues and adjacent normal breast tissues as analyzed by the qRT-PCR assay. (B) The expression of miR-205 in breast cancer cell lines and normal cell MCF10A. (C) The expression of miR-205 in breast cancer patients with TNM stages was significantly reduced. (D) Both MCF7 and MDA-MB-231 cells were transfected with control miRNA or miR-205 mimics, and the expression of miR-205 was confirmed by qRT-PCR. (E) The association between expression of miR-205 and clinical characteristics of patients with breast cancer. LinkedOmics database with TCGA data was used for this analysis. All experiments were carried out in triplicate. Data were expressed as mean ± standard deviation (SD).